Zynex Inc. (OTCMKTS:ZYXI) CFO Daniel J. Moorhead sold 13,750 shares of the business’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $8.25, for a total value of $113,437.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
OTCMKTS ZYXI opened at $8.80 on Friday. Zynex Inc. has a fifty-two week low of $2.40 and a fifty-two week high of $9.22. The firm has a market capitalization of $283.76 million, a PE ratio of 40.00 and a beta of 1.05.
Zynex (OTCMKTS:ZYXI) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.07 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.05 by $0.02. Zynex had a return on equity of 152.81% and a net margin of 33.33%. The company had revenue of $9.20 million during the quarter, compared to analysts’ expectations of $8.45 million. Equities research analysts anticipate that Zynex Inc. will post 0.28 EPS for the current year.
Several large investors have recently made changes to their positions in the company. ExodusPoint Capital Management LP purchased a new stake in shares of Zynex in the first quarter valued at $45,000. Sigma Planning Corp purchased a new stake in shares of Zynex in the first quarter valued at $63,000. O Shaughnessy Asset Management LLC purchased a new stake in shares of Zynex in the first quarter valued at $118,000. WealthTrust Axiom LLC purchased a new stake in shares of Zynex in the first quarter valued at $132,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of Zynex in the first quarter valued at $215,000. 0.05% of the stock is owned by institutional investors and hedge funds.
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Featured Article: Mutual Funds
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.